CDEK
← All drugs Report issue

linsitinib

Small moleculeexperimental

Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis. — Wikipedia

Clinical trial activity

26 trials · 22 clinical orgs · 0 marketing orgs

Phase 1
11
Phase 2
17
Phase 3
3
Phase 4
0

Earliest trial started Dec 1, 2006 (NCT00514007)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1
Mol. weight
421.5 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
  • asp7487
  • asp-7487
  • asp-7487
  • linsitinib
  • linsitinib
  • linsitinib
  • linsitinib
  • osi906
  • osi 906
  • osi-906
  • osi-906
  • osi-906
  • osi-906
  • osi-906aa
  • osi-906aa

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06112340Phase 2/Phase 3 (Phase 3)Oct 11, 2023Sling Therapeutics, Inc.
NCT05276063Phase 2/Phase 3 (Phase 3)Jul 1, 2022Sling Therapeutics, Inc.
NCT02057380Phase 2Apr 1, 2014Astellas
NCT02546544Phase 2Mar 1, 2014Astellas, European Commission, European Organisation for Research and Treatment of Cancer, University of Oxford
NCT01427205Phase 2Jun 1, 2013OSI Pharmaceuticals, University of Texas at Houston
NCT01672736Phase 1/Phase 2 (Phase 2)Sep 1, 2012Astellas, Multiple Myeloma Research Consortium, University of Toronto
NCT01567384Phase 1May 1, 2012Emory University, OSI Pharmaceuticals
NCT01560260Phase 2Mar 1, 2012National Cancer Institute (NCI), Sarcoma Alliance for Research through Collaboration
NCT01533181Phase 2Feb 1, 2012National Cancer Institute (NCI), University of South Florida
NCT01533246Phase 2Feb 1, 2012National Cancer Institute (NCI), University of Rochester
NCT01529684Phase 1Jan 1, 2012Astellas
NCT01221077Phase 2Dec 1, 2011Astellas
NCT01465815Phase 1/Phase 2 (Phase 2)Dec 1, 2011National Cancer Institute (NCI), Oregon Health and Science University
NCT01600807Phase 1/Phase 2 (Phase 2)Aug 8, 2011Harvard University
NCT01334710Phase 2Mar 1, 2011Emory University, OSI Pharmaceuticals
NCT01186861Phase 2Dec 1, 2010Astellas
NCT01101906Phase 2Oct 1, 2010Astellas
NCT01154335Phase 1Jul 1, 2010Novartis, OSI Pharmaceuticals, SCRI Development Innovations
NCT01205685Phase 2May 1, 2010Vanderbilt University
NCT01016860Phase 1Dec 1, 2009University of Colorado, Denver
Showing 20 of 26 trials
Page 1 / 2

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstellasFor profit121032006
National Cancer Institute (NCI)Government5312009
OSI PharmaceuticalsFor profit4022010
Emory UniversityAcademic/Hospital2222011
Sling Therapeutics, Inc.For profit2212022
Vanderbilt UniversityAcademic/Hospital2212009
Charles UniversityAcademic/Hospital1012009
European CommissionGovernment1012014
European Organisation for Research and Treatment of CancerAcademic/Hospital1012014
Harvard UniversityAcademic/Hospital1112011
Instituto Europeo de OncologiaAcademic/Hospital1012009
Multiple Myeloma Research ConsortiumAcademic/Hospital1012012
NovartisFor profit1012010
Oregon Health and Science UniversityAcademic/Hospital1112011
Sarcoma Alliance for Research through CollaborationAcademic/Hospital1012012
SCRI Development InnovationsFor profit1112010
University of Colorado, DenverAcademic/Hospital1112009
University of OxfordAcademic/Hospital1112014
University of RochesterAcademic/Hospital1012012
University of South FloridaAcademic/Hospital1012012
22 organizations
Page 1 / 2